Pharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer

Journal of Immunotherapy

Volumn 26, Issue 2, 2003, Pages 139-148

  Crombet, Tania ^a   Torres, Leonel ^a   Neninger, Elia ^a   Catalá, Mauricio ^a   Solano, María E ^a   Perera, Alejandro ^b   Torres, Olga ^b   Iznaga, Normando ^b   Torres, Franz ^b   Pérez, Rolando ^b   Lage, Agustín ^b  

^a Center for Clinical Research   (United States)

^b Hermanos Ameijeiras Hospital   (United States)

Author keywords

Epidermal growth factor receptor; Monoclonal antibody; Phase I clinical trial

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPITOPE; HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY R3; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ANTIBODY LABELING; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FLUSHING; HUMAN; HYPERTENSION; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TREMOR; TUMOR GROWTH; VOMITING; WHOLE BODY SCINTISCANNING; WORLD HEALTH ORGANIZATION; XEROSTOMIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOLOGICAL AVAILABILITY; CARCINOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0037336316     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200303000-00006     Document Type: Article

References (56)

1. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res. 2001; 7:1850-1855.
2. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001; 37(Suppl 4):9-15.
3. Libermann TA, Razon N, Bartal AD, et al. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res. 1984; 4:753-760.
4. FeldKamp MM, Lau N, Guha A. Signal transduction pathways and their relevance in human astrocytomas. Cancer Immunol Immunother. 1997; 44:157-164.
5. Kearsley JH, Leonard JH, Walsh MD, et al. A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas. Pathology. 1991; 23:189-194.
6. Rikimaru K, Tadokoro K, Yamamoto T, et al. Gene amplification and overexpression of epidermal growth factor receptor in squamous cell carcinoma of the head and neck. Head Neck. 1992; 14:8-13.
7. Alper O, Bergmann-Leitner ES, Bennett TA, et al. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Ins. 2001; 93:1375-1384.
8. Bianco C, Bianco R, Tortora G, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res. 2000; 6:4343-4350.
9. Ngan HY, Cheung AN, Liu SS, et al. Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: correlation with human papillomavirus and prognosis. Tumor Biol. 2001; 22:176-183.
10. Chow NH, Chan SH, Tzai TS, et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res. 2001; 7:1957-1962.
11. Inada S, Koto T, Futami K, et al. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today. 1999; 29:493-503.
12. Wang LS, Chow KC, Chi KH. Prognosis of esophageal squamous cell carcinoma: analysis of clinicopathologic and biologic factors. Am J Gastroenterol. 1999; 94:1933-1940.
13. Giordano A, Rustum YM, Wenner CE. Cell cycle: molecular targets for diagnosis and therapy: tumor suppressor genes and cell cycle progression in cancer. J Cell Biochem. 1998; 70:1-7.
14. Damstrup L, Rude Voldborg B, Spang-Thomsen M, et al. In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor. Br J Cancer. 1998; 78:631-640.
15. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997; 151:1523-1530.
16. Kerbel RS, Viloria-Petit A, Okada F, et al. Establishing a link between oncogenes and tumor angiogenesis. Mol Med. 1998; 4:286-295.
17. Gibson S, Tu S, Oyer R, et al. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem. 1999; 274:17612-17618.
18. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000; 19:6550-6565.
19. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol. 2001; 13:506-513.
20. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001; 7:2958-70.
21. Fernández A, Pérez R, Macías A, et al. Generation and characterization of anti-EGFR antibodies. Interferon y Biotecnología. 1989; 6:289-298.
22. Fernández A, Spitzer E, Pérez R, et al. A new monoclonal antibody for detection of the EGF-R in Western Blot and paraffin embedded tissue sections. J Cell Biochem. 1992; 49:157-165.
23. Crombet T, Torres O, Neninger E, et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor. Cancer Biother Radiopharm. 2001; 16:93-102.
24. Crombet T, Torres O, Rodriguez V, et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study. Hybridoma. 2001; 20:131-136.
25. Ramos-Suzarte M, Rodriguez N, Oliva JP, et al. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy. J Nucl Med. 1999; 40:768-775.
26. Mateo C, Moreno E, Amour K, et al. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology. 1997; 3:71-81.
27. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001; 61:5090-5101.
28. Crombet-Ramos T, Rak J, Perez R, et al. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer. 2002; 101:567-575.
29. Stragliotto G, Vega F, Stasiecki P et al. Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur J Cancer. 1996; 32A:636-640.
30. Edwards IR. Harmonisation in pharmacovigilance. Drug Saf. 1994; 10:93.
31. Schwarz A, Steinstraber A. A novel approach to Tc-99m-labeled monoclonal antibodies. J Nucl Med. 1987; 28:721-727.
32. Iznaga Escobar N, Morales AM, Duconge J, et al. Pharmacokinetics, biodistribution and dosimetry of 99mTc-labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats. Nucl Med Biol. 1998; 25:17-23.
33. Morales AA, Duconge J, Alvarez-Ruiz D, et al. Humanized versus murine anti-human epidermal growth factor receptor monoclonal antibodies for immunoscintigraphic studies. Nucl Med Biol. 2000; 27:199-206.
34. Macias A, Pérez R, Lage A. Estudios sobre el factor de crecimiento epidérmico (EGF) II: Desarrollo de un radioreceptor analisis para la determinación de cantidades picomolares. Interferon y Biotecnología. 1985; 2:115-127.
35. Akaike A. Posterior probabilities for choosing regression models. Ann Inst Math Stat. 1978; 30:A9.
36. Rosenberg S. Principles of Cancer Management: Biologic Therapy. In: De Vita V, Hellman S, Rosemberg S, eds. Cancer: Principles and Practice of Oncology 2001. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:307-334.
37. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs. 2000; 60(suppl 1): 25:41-42.
38. Slamon D, Leyland B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against Her 2 for metastatic breast cancer that overexpresses Her 2. N Engl J Med. 2000; 344:783-792.
39. Davis TA, Grillo-López AJ, White CA, et al. RituximAb anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000; 18:3135-3143.
40. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended RituximAb (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 2000; 10:655-661.
41. Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001; 98:1721-1726.
42. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumAb ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001; 7:1490-1496.
43. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001; 144:1169-1176.
44. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res. 2001; 7:1204-1212.
45. Figlin R, Belldegrun A, Lohner M, et al. ABX-EGF: a fully human anti-EGF receptor antibody in patients with advanced cancer [abstract]. Proc Am Soc Clin Oncol. 2001; 20:276a.
46. Meric JB, Faivre S, Monnerat C, et al. Zd 1839 “Iressa” Bull Cancer. 2000; 87:873-876.
47. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001; 19:3267-3279.
48. Stroomer JW, Roos JC, Sproll M, et al. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin Cancer Res. 2000; 6:3046-3055.
49. Iznaga-Escobar N, Torres LA, Morales A, et al. Tm-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy. J Nucl Med. 1998; 15:18-27.
50. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000; 18:904-914.
51. Bier H, Hoffmann T, Hauser U, et al. Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmac. 2001; 47:519-524.
52. Partanen R, Hemminki K, Koskinen H, et al. The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients. J Occup Med. 1994; 36:1324-1328.
53. Choi JH, Oh JY, Ryu SK, et al. Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients. Cancer. 1997; 79:1879-1883.
54. Oh MJ, Choi JH, Kim IH, et al. Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. Clin Cancer Res. 2000; 6:4760-4763.
55. Sharma BK, Ray A, Kaur S, et al. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumor suppressor (p53) protein, EGF-R and EMA in histologic subtypes of infiltrating duct carcinoma of the breast. Indian J Exp Biol. 1999; 37:223-227.
56. Umekita Y, Ohi Y, Sagara Y, et al. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients. Int J Cancer. 2000; 89:484-487.